Review shows 2 to 3 g/day may be optimal intake associated with both systolic and diastolic blood pressure reductions
WEDNESDAY, June 8, 2022 (HealthDay News) — The optimal combined intake of omega-3 fatty acids associated with reductions in blood pressure (BP) appears to be between 2 and 3 g/day, according to a meta-analysis published in the June 7 issue of the Journal of the American Heart Association.
Xin Zhang, Ph.D., from the Macau University of Science and Technology in China, and colleagues conducted a systematic review to examine the association between omega-3 fatty acids and BP. Data were included from 71 trials of 4,973 individuals with a combined docosahexaenoic acid (DHA) + eicosapentaenoic (EPA) acid dose of 2.8 g/day (interquartile range, 1.3 to 3.6 g/day).
The researchers identified a nonlinear association overall, and in most subgroups, the association was depicted as J-shaped dose-response curves. Moderate doses of 2 to 3 g/day were the optimal intake for both systolic and diastolic BP reductions (−2.61 and −1.64 mm Hg for 2 g/day and −2.61 and −1.80 mm Hg for 3 g/day). Stronger and approximately linear dose-response relations among hypertensive, hyperlipidemic, and older populations were seen in subgroup studies.
“Our study supports the [U.S. Food and Drug Administration] guidance that EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease by lowering high BP, especially among people already diagnosed with hypertension,” a coauthor said in a statement. “However, while our study may add a layer of credible evidence, it does not meet the threshold to make an authorized health claim for omega-3 fatty acids in compliance with FDA regulations.”
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Isometric Exercise Training Three Times a Week Preserves Cardiovascular Benefits
IBD Not Linked to Risk for Hypertensive Disorders of Pregnancy Overall
Low Levels of Placental Growth Factor in Pregnancy Linked to Subsequent ADHD in Offspring
Recommendations Issued for Use of Incretin-Based Meds in Pregnancy
Serum 25(OH)D May Serve as Biomarker of Disease Activity in IBD
Maternal Vitamin D Status Linked to Preterm Delivery